Immunotherapy, specifically immune checkpoint inhibitors (ICIs), has become a standard cancer treatment.
However, 20-40% of patients suffer from cutaneous adverse events while receiving it.
A new study challenges the perception that these effects should only be treated as a negative outcome.
The researchers compared medical information of more than 14,000 advanced cancer patients who received ICIs, half who experienced skin-related side effects and half who did not.
They have found that those who experienced at least one skin-related adverse event had a 22% decrease in mortality.
They concluded that these side effects might be linked to better response to ICIs and improved survival.
More studies are required to understand the mechanism underlying these findings.
developments
For more info:
At Belong, we will continue to update you with new medical and research
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment.
